GSK, Therapeutics and Rapt
Digest more
GSK acquires Rapt Therapeutics for $2.2B. Stock surges 65% as pharma giant gains access to phase 2b food allergy treatment ...
Shares of Rapt Therapeutics ( RAPT +64.02%) surged on Tuesday after the immunology specialist struck a deal to be acquired by ...
If you are wondering whether GSK shares still offer value at around £18.86, you are not alone. The stock has been attracting ...
RAPT Therapeutics' stock jumped more than 63% during the pre-market trading session on the US stock market after GSK Plc ...
Stocktwits on MSN
Why did RAPT stock surge 63% in pre-market today?
GSK signed an agreement to acquire RAPT Therapeutics for around $2.2 billion. ・The deal centers on an experimental allergy ...
GSK (LSE:GSK) has been on investor radars after recent trading performance, with the share price showing a 1.1% decline over ...
Zacks.com on MSN
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?
Bristol Myers Squibb and GSK stack up differently on growth, debt, pipelines and returns, making the stock-picking decision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback